Role of Advanced Screening Technologies in Early Detection of Breast Cancer
Role of Advanced Screening Technologies in Early Detection of Breast Cancer
批准号:
7827475
负责人:
Sandra J Lee
金额:
$43.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-08-31
关键词:
AddressAgeAreaBreastBreast Cancer DetectionBreast Cancer Early DetectionCancer Intervention and Surveillance Modeling NetworkClinical TrialsContralateralDataDetectionDiagnosisDigital MammographyDiseaseEarly DiagnosisEffectivenessFamily history ofFilmGenetic Predisposition to DiseaseGoalsGrantImageLeadMagnetic Resonance ImagingMammographyModalityModelingNatural HistoryPopulationProcessProgressive DiseaseRandomized Clinical TrialsRandomized Controlled Clinical TrialsRecommendationReportingResearchRiskRisk FactorsRoleSavingsScheduleScreening procedureSpecific qualifier valueStagingTargeted ResearchTechnologyTimeWomanabstractingbasebreast cancer diagnosisbreast densitycancer riskcomparative effectivenessdigitaldisease natural historyeffectiveness researchhigh riskimprovedmalignant breast neoplasmmathematical modelmortalitypre-clinicalprogramspublic health relevancetransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Role of Advanced Screening Technologies for Early Detection of Breast Cancer Project Summary/Abstract This application addresses broad Challenge Area (05): Comparative Effectiveness Research and specific Challenge Topic, 05-CA-105 CISNET (The Cancer Intervention and Surveillance Modeling Network). The goals of this research are targeted at evaluating the benefits associated with advanced screening technologies for breast cancer screening. It is planned to apply the stochastic model developed by Lee and Zelen (2008) to address the effectiveness of advanced screening technologies in the early detection of breast cancer. The Lee-Zelen model (2008) has been developed as part of the CISNET breast group. The model predicts breast cancer mortality as a function of the disease natural history and detection process. The principal assumptions of the model are that: i) breast cancer is a progressive disease and ii) mortality benefit from screening is due to a stage shift in diagnosis. Among the rapidly emerging advanced screening technologies, digital mammography (DM) and magnetic resonance imaging (MRI) have been reported to be more sensitive in diagnosing breast cancer. However the mortality benefit associated with these screening modalities has not been evaluated. This grant will focus on evaluating the mortality benefit from DM and MRI screening. The digital mammographic imaging screening trial showed that DM was significantly more sensitive than film mammography in screening women under age 50 or women of any age with very dense breasts (Pisano et al., 2005). MRI has been shown to be more sensitive than mammography in detecting breast cancer in women with inherited susceptibility to breast cancer (Kreige et al., 2004; Leach et al., 2005). An important issue which will be investigated deals with optimal screening strategies using DM and MRI. A screening program is characterized by: i) the age to begin a screening program, ii) the times between examinations and 3) possibly the age to end screening. There are so many potential permutations of these variables that clinical trials cannot possibly examine all of the possible permutations. Furthermore randomized trials are not feasible. The only way to investigate the problem is to have an analytical model of the screening process which incorporates the main features of the disease and the screening process. The potential savings of having screening programs based on risk are enormous. Specifically it is planned to: Estimate the mortality benefit of DM in women under age 50 and women of any age with dense breasts. Estimate the potential mortality benefit of DM if disseminated in the U.S. population. Estimate the mortality benefit of MRI in women with elevated risk of developing breast cancer. Find optimal screening exam schedules which depend on breast density. Investigate optimal screening strategies by risk status for DM and MRI screening modalities. Role of Advanced Screening Technologies for Early Detection of Breast Cancer
PUBLIC HEALTH RELEVANCE: Magnetic resonance imaging (MRI) may be utilized for breast cancer screening in high risk populations and digital mammography may be advantageous for screening women with dense breasts. This project will use the Lee-Zelen's (2008) mathematical model to evaluate mortality benefit as well as to find optimal screening strategies for these advanced screening modalities. As it is difficult to investigate these problems using randomized clinical trials, mathematical models can make a significant contribution in understanding the potential gain from these screening modalities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparative Assessment of Screening Strategies for Melanoma
-
批准号:8757665
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2014
-
负责人:Sandra J Lee
-
依托单位:
Analytical Investigation of Breast Cancer Progression: DCIS, Overdiagnosis
-
批准号:8522172
-
项目类别:
-
资助金额:$36.45万
-
财政年份:2012
-
负责人:Sandra J Lee
-
依托单位:
Analytical Investigation of Breast Cancer Progression: DCIS, Overdiagnosis
-
批准号:9069764
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2012
-
负责人:Sandra J Lee
-
依托单位:
Analytical Investigation of Breast Cancer Progression: DCIS, Overdiagnosis
-
批准号:8371645
-
项目类别:
-
资助金额:$39.22万
-
财政年份:2012
-
负责人:Sandra J Lee
-
依托单位:
Analytical Investigation of Breast Cancer Progression: DCIS, Overdiagnosis
-
批准号:8676739
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2012
-
负责人:Sandra J Lee
-
依托单位:
Breast Cancer: Role of Early Detection, Treatment and Prevention
-
批准号:7916304
-
项目类别:
-
资助金额:$9.98万
-
财政年份:2009
-
负责人:Sandra J Lee
-
依托单位:
Role of Advanced Screening Technologies in Early Detection of Breast Cancer
-
批准号:7944030
-
项目类别:
-
资助金额:$40.21万
-
财政年份:2009
-
负责人:Sandra J Lee
-
依托单位:
Breast Cancer: Role of Early Detection, Treatment and Prevention
-
批准号:7277143
-
项目类别:
-
资助金额:$24.62万
-
财政年份:2000
-
负责人:Sandra J Lee
-
依托单位:
Breast Cancer: Role of Early Detection, Treatment and Prevention
-
批准号:7498556
-
项目类别:
-
资助金额:$24.76万
-
财政年份:2000
-
负责人:Sandra J Lee
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: